Here are six key trends:
1. The Asia-Pacific region has witnessed rapid market growth in the orthopedic biomaterials segment. This is due to a number of reasons, including the income per capita has increased significantly in China and India since the year 2000, allowing for better healthcare budgets.
2. The Australia and South Korea biologics markets are both in the mature stages of development.
3. Local Asia-Pacific competitors in the market, such as Seikagaku, Meiji Seika Kaisha and Shin Poong, are leading in several biologics segments due to regulatory government support.
4. Global players are succeeding to some extent in the Asia-Pacific biomaterials market. Medtronic was the largest competitor in the Australian biologics market in 2015 with its synthetic grafts as well as its BMP-2 based INFUSE product.
5. Genzyme was the largest player in the Indian biologics market in 2015 with its Synvisc and SynviscOne HA products.
6. Within the Indian bone grafts substitutes market specifically, DePuy Synthes was the leader in terms of sales with its synthetic-based ChronosOn product portfolio.
More articles on devices:
OrthoSecure changes name to OrthoLogix, launches implant management technology — 4 things to know
Myoscience’s iovera reaches maximum enrollment for 2 knee pain studies — 6 takeaways
Nationwide Fund Advisors purchases $26.4M Zimmer Biomet stake: 5 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
